| Literature DB >> 35366734 |
Özgür Öcal1, Aymer Coşar2, Mustafa Nazıroğlu3,4,5.
Abstract
The hypoxia (HPX) acts the brain injury and apoptosis via the Ca2+ influx-induced excessive mitochondria free reactive oxygen species (mitROS) in neurons. The effective treatment of HPX is not possible yet. In addition to the antiviral and antiparkinsonian actions, amantadine (AMN) has been evaluated as a drug in treatments against brain injury. TRPM2 and TRPV4 channels are activated by mitROS. AMN attenuates NMDA receptor-induced Ca2+ influx, mitROS, inflammation, and apoptosis in the brain. However, the molecular pathways underlying AMN's neuroprotection against HPX remain elusive. We investigated the protective role of AMN via attenuation of TRPM2 and TRPV4 on oxidative neurotoxicity, mitochondrial membrane potential (ΔΨm), inflammation, and apoptosis in neuronal cells (SH-SY5Y). The SH-SY5Y and HEK293 cells were divided into six groups as follows: control, AMN (750 µM for 48 h), HPX (200 µM CoCl2 for 24 h), HPX + AMN, HPX + TRPM2 blockers (25 µM ACA or 100 µM 2APB for 30 min), and HPX + TRPV4 blocker (ruthenium red (RuR)-1 µM for 30 min). The HPX caused to upregulation of Ca2+ influx with an upregulation of ΔΨm and mitROS. The changes were not observed in the absence of TRPM2 and TRPV4 in the HEK293 cells. When HPX induction, TRPV4 agonist (GSK1016790A) and TRPM2 agonists (ADP-ribose and H2O2)-induced channel activity were diminished by the incubation of AMN and channel antagonists (RuR, ACA, and 2APB). The changes of mitROS, apoptotic markers (caspase-3 and -9), cell death rate, cell viability, cytokine (IL-1β, IL-6, and TNF-α), ΔΨm, and Zn2+ concentrations were also restored by the incubation of AMN. In conclusion, the treatment of AMN attenuated HPX-mediated mitROS, apoptosis, and TRPM2/TRPV4-mediated overload Ca2+ influx and may provide an avenue for protecting the HPX-mediated neurodegenerative and cerebrovascular diseases associated with the upregulation of mitROS, Ca2+, and Zn2+ concentration.Entities:
Keywords: Amantadine; Cerebrovascular disease; Hypoxia; Oxidative neurotoxicity; TRPM2; TRPV4
Mesh:
Substances:
Year: 2022 PMID: 35366734 DOI: 10.1007/s12035-022-02814-6
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.590